Skip to main content

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA

Publication: JAMA (2015) • Vol 313 • Page 390-7PMID: 25626035View on PubMed

Purpose

The purpose of this paper was to compare the efficacy of targeted multiparametric magnetic resonance imaging (MP-MRI)-guided  and standard transrectal ultrasound (TRUS)- guided biopsy methods for the identification of high- and low-risk prostate cancer. 

Conclusion

Exact agreement between standard transrectal ultrasound (TRUS)-guided and targeted multiparametric magnetic resonance imaging (MP-MRI)-guided biopsies was observed in 69% of patients (690/1003).  While the number of cancer-positive cases were similar between biopsy methods (461 vs 469 for MP-MRI- and TRUS-guided biopsies, respectively), the MP-MRI-guided biopsy method resulted in significantly more high-risk cancers than the TRUS-guided biopsy method (173 vs 122 cases; p<0.001), but significantly fewer low-risk cancers (213 vs 258 cases; P=0.002).  When biopsy methods were compared to results obtained with a subsequent prostatectomy in a patient subset (170 cases), the sensitivity of the targeted MP-MRI biopsy method was determined to be 77% compared to 53% for the standard TRUS-guided biopsy method.  

Studies (1)

Purpose

The purpose of this study was to compare the efficacy of targeted multiparametric magnetic resonance imaging (MP-MRI)- and standard transrectal ultrasound (TRUS)-guided biopsy methods for the identification of high- and low-risk prostate cancer. Biopsy specimens were first procured using MP-MRI guidance by one physician, after which standard biopsies were procured using TRUS guidance by a different physician.  A mean of 12 TRUS-guided biopsy cores were obtained from each patient, while the mean number of cores obtained by MP-MRI was not reported. Case-matched biopsies were procured from 1003 patients, 170 of which later underwent a radical prostatectomy.   Tumors were classified as low-risk when a Gleason score of 6 was assigned; as intermediate risk if a Gleason score of 3+4 was assigned and 50% of more of any core contained cancerous cells or 33% or more of standard biopsy cores were positive for cancer; and as high-risk if a Gleason score of 4+3 or greater was assigned.

Summary of Findings

Exact agreement between standard TRUS-guided and MP-MRI guided biopsies was observed in 69% of patients (690/1003).  While the number of cancer-positive cases were similar between biopsy methods (461 vs 469 for MP-MRI guided and TRUS-guided biopsies, respectively), the MP-MRI guided biopsy method resulted in significantly more high-risk cancers than the TRUS-guided biopsy method (173 vs 122 cases; p<0.001), but significantly fewer low-risk cancers (213 vs 258 cases; P=0.002).  When biopsies procured using different methods were considered in combination, a diagnosis of cancer increased by 22%, although 83% of these 103 cases were low-risk.  When biopsy methods were compared to results obtained with a subsequent prostatectomy in a patient subset (170 cases), 17 patients were diagnosed with prostate cancer based on the TRUS-guided biopsy, but only 3 were diagnosed as intermediate- or high-risk cancer based on the prostatectomy specimen. Similarly, 20 patients were diagnosed with prostate cancer based on the MP-MRI-guided biopsy, but only  12 were diagnosed with intermediate- or high-risk cancer based on the prostatectomy specimen. Based on this patient subset, the sensitivity of the targeted MP-MRI biopsy method was determined to be 77% compared to 53% for the standard TRUS-guided biopsy method. 

  • Biospecimens

    TissueProstate
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    MorphologyH-and-E microscopy
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionMethod of tissue acquisition
    Magnetic resonance imaging-guided biopsy
    Surgical resection
    Ultrasound-guided biopsy